Optimizing the antitumor efficacy of cisplatin low doses by the co-treatment with ethylenediamine tetra acetic acid in EAC-bearing mice
El-Bolkiny, Y., Makboul, F., Elwan, M. (2024). Optimizing the antitumor efficacy of cisplatin low doses by the co-treatment with ethylenediamine tetra acetic acid in EAC-bearing mice. EKB Journal Management System, 2(1), 56-66. doi: 10.21608/bbj.2024.341812
Yousry El-Bolkiny; Fatehyia Makboul; Mona Elwan. "Optimizing the antitumor efficacy of cisplatin low doses by the co-treatment with ethylenediamine tetra acetic acid in EAC-bearing mice". EKB Journal Management System, 2, 1, 2024, 56-66. doi: 10.21608/bbj.2024.341812
El-Bolkiny, Y., Makboul, F., Elwan, M. (2024). 'Optimizing the antitumor efficacy of cisplatin low doses by the co-treatment with ethylenediamine tetra acetic acid in EAC-bearing mice', EKB Journal Management System, 2(1), pp. 56-66. doi: 10.21608/bbj.2024.341812
El-Bolkiny, Y., Makboul, F., Elwan, M. Optimizing the antitumor efficacy of cisplatin low doses by the co-treatment with ethylenediamine tetra acetic acid in EAC-bearing mice. EKB Journal Management System, 2024; 2(1): 56-66. doi: 10.21608/bbj.2024.341812

Optimizing the antitumor efficacy of cisplatin low doses by the co-treatment with ethylenediamine tetra acetic acid in EAC-bearing mice

Biological and Biomedical Journal
Volume 2, Issue 1, February 2024, Page 56-66  XML PDF (558.96 K)
Document Type: Research Articles
DOI: 10.21608/bbj.2024.341812
View on SCiNiTO View on SCiNiTO
Authors
Yousry El-Bolkiny email 1; Fatehyia Makboul; Mona Elwan email 2
1Zoology Department, Faculty of Science, Tanta University
2Histology, Zoology Department, Tanta University
Abstract
Cancer disease remains one of the most cause of death worldwide. The
drawbacks that were associated to the chemotherapy treatments are impetus
for finding more efficacious, and better tolerated new drugs. This study was
conducted to optimize the low doses of cisplatin (Cis) antitumor effect by the
co-treatment of ethylenediamine tetra acetic acid (EDTA) in EAC-bearing
mice. Sixty-four female CD-1 mice were divided into eight groups (n = 8) as
follows: Gp1 was a negative control. Gp2 had inoculated with 1×106 EACcells/mouse interperitoneally (i.p.). Gp3, Gp4 and Gp5 had inoculated with
the same number of EAC-cells as in Gp2, then injected with 0.125, 0.250 or
0.5 mg/Kg of Cis i.p, respectively. Gp6, Gp7 and Gp8 had inoculated with
EAC-cells as in Gp2, then injected with the low doses of Cis as in Gp3- G5
in combination with EDTA (50 mg/Kg), respectively. At day 14, all groups
were bled to collect sera for biochemical assessments. The tumor ascites was
collected for determining the total tumor volume and total tumor counts.
Liver tissues were harvested for histopathological investigations. The results
showed that co-treatment of EDTA (50 mg/Kg) along with the low doses of
Cis (0.125, 0.25 or 50 mg/Kg) led to significant reduction in tumor volume,
tumor cells count, improved the liver, kidney functions, and antioxidant
status. Among all the treated EAC-bearing mice groups, mice that had a
combined treatment with Cis (0.5 mg/Kg) and EDTA (50 mg/Kg) showed
the highest antitumor effect with highly improvements in the liver functions
and architectures. 
Keywords
Antitumor; Cisplatin; Ethylenediamine tetra acetic acid; EAC-bearing mice
Statistics
Article View: 54
PDF Download: 51